An international consortium of researchers, including major contribution from a team led by Dr. John D. Rioux, a professor of medicine at the Université de Montréal and the Montreal Heart Institute, has identified genetic markers associated with risk for ulcerative colitis.

An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis.

It is believed that the generation of an exaggerated intestinal immune response to otherwise innocuous stimuli along with generation of oxygen free radicals plays a key role in the pathophysiology of UC.

Although exacerbation of UC usually poses little diagnostic dilemma, physicians should remain cognizant to the possibility of an alternative cause for patient symptoms.

Shire Limited, the global specialty biopharmaceutical company, announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda™ (mesalamine).

Two research studies evaluating dietary changes and complementary medicine for the treatment of inflammatory bowel diseases (IBD) have been launched at Rush University Medical Center.

Using new genetic techniques, scientists are unlocking the secrets of how E coli bacteria contaminate food and make people sick.

Medical Therapies Limited today announced that it has completed its ‘first in human’ clinical trial of Cuprindo with interim results from patient diaries indicating that Cuprindo™ is safe and well tolerated.

Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented today at the 2007 Crohn’s & Colitis Foundation’s 6th Annual Advances in the Inflammatory Bowel Diseases conference.

Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis (UC), including isolated proctitis.

A pilot study from researchers at Kyushu University in Fukuoka, Japan, found that narrow band imaging (NBI) colonoscopy used in cancer surveillance for ulcerative colitis patients can identify flat dysplastic lesions. The research appears in the November issue of Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy.

Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years. Unfortunately, the etiology and pathogenesis of ulcerative colitis have not been clarified yet.